Baxdela (delafloxacin) / Menarini, Melinta Therap, Ligand - LARVOL DELTA

Molecular resistance mechanisms to newly approved antibiotics (2017-2025) in WHO priority pathogens. (PubMed, Front Microbiol) - "This review systematically summarizes the molecular resistance mechanisms that World Health Organization (WHO) priority bacterial pathogens have already deployed against the 15 new antibiotics approved between 2017 and 2025, including β-lactam/β-lactamase inhibitors (cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam), tetracycline derivatives (eravacycline, omadacycline), a pleuromutilin (lefamulin), an aminoglycoside (plazomicin), and a fluoroquinolone (delafloxacin). Preserving the efficacy of these essential drugs thus necessitates a multifaceted, globally coordinated "One Health" strategy. Finally, we discuss how the growing complexity of AMR mechanisms is driving the need for advanced diagnostic tools, exploring the pivotal role of bioinformatics and artificial intelligence in predicting resistance and closing knowledge gaps."

Journal • Review

Unraveling ciprofloxacin and delafloxacin efficacy and resistance evolution at multiple concentrations on Pseudomonas aeruginosa infection dynamics; results from a human bronchial epithelium model (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease

pH-dependent resistance evolution of delafloxacin (DLX) and ciprofloxacin (CIP) in Pseudomonas aeruginosa from cystic fibrosis (CF) and non-CF patients (ESCMID Global 2026) - No abstract available

Clinical • Cystic Fibrosis • Genetic Disorders • Immunology • Respiratory Diseases

Comparative activity of delafloxacin and linezolid against methicillin-resistant Staphylococcus aureus (MRSA) biofilm: results of an in vitro dynamic model (ESCMID Global 2026) - No abstract available

Preclinical • Infectious Disease

In vitro activity of delafloxacin vs ciprofloxacin, levofloxacin and moxifloxacin against MRSA (ESCMID Global 2026) - No abstract available

Preclinical

Delafloxacin beyond the label: early clinical experience against fluoroquinolone-resistant infections (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease

Activity of ciprofloxacin vs delafloxacin in acidic environments: impact of SOS response inactivation in Escherichia coli (ESCMID Global 2026) - No abstract available

IPT13 - Fluoroquinolones: friends or foes? One size does not fit all (ESCMID Global 2026) - "Expert speakers will review key clinical data, illustrating its performance alongside a discussion of its safety profile, particularly regarding traditional fluoroquinolones. Attendees will gain a clear, evidence-based understanding of how delafloxacin differentiates from other FQs and its potential role in the treatment of ABSSSI."

Infectious Disease

Model-integrated evidence for delafloxacin: minimal PBPK simulations and network meta-analysis to support urinary tract infection indication development (ESCMID Global 2026) - No abstract available

Retrospective data • Infectious Disease • Nephrology

Synergistic activity of a phage cocktail and delafloxacin against Pseudomonas aeruginosa biofilms (ESCMID Global 2026) - No abstract available

Efficacy and safety of delafloxacin for musculoskeletal infections caused by levofloxacin-resistant staphylococci: experience from a multi-centre cohort (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease • Musculoskeletal Diseases

Synthesis of Enduracididine Free Linear Teixobactin Analogs: Molecular Docking, DFT Calculations, and Their Antimicrobial Activities, Bacterial Cell Wall Lysis and Glucose Assay. (PubMed, Curr Med Chem) - "Mass, 1H NMR, and HPLC analysis characterized the synthesized fine TX analogs (TX1-TX5). The DFT and docking studies' electronic characteristic calculations predicted that halogenated (TX1, TX2, and TX4) and methoxy (TX3) substituted analogs have higher stability and electrophilicity, making them suitable agents for antimicrobial activity."

Journal • Infectious Disease

Evaluation of cerebrospinal fluid penetration of delafloxacin in a murine model. (PubMed, Antimicrob Agents Chemother) - "The CSF penetration ratio of delafloxacin was 49%. Cmax/MIC ratios met pharmacokinetic/pharmacodynamic targets for Staphylococcus and Streptococcus spp., but not Enterobacterales."

Journal • Preclinical

In vitro antibiofilm and intracellular activity of delafloxacin against Staphylococcus aureus and Staphylococcus epidermidis in bone and joint infections. (PubMed, Microbiol Spectr) - "The 90% minimal biofilm eradication concentration (MBEC90) of delafloxacin was compared with that of rifampicin, vancomycin, and levofloxacin after a 24-h treatment of biofilm-embedded staphylococci. However, its efficacy against levofloxacin-resistant strains was variable and appeared to be strain-dependent, both in biofilm and intracellular conditions. This study confirms the promising potential of delafloxacin to treat staphylococcal BJIs, but further investigations, including animal models and clinical trials, are needed to better understand its efficacy."

Journal • Preclinical • Infectious Disease

Modulators of gene amplification alter evolution of antibiotic resistance in Staphylococcus aureus. (PubMed, PLoS Genet) - "We previously showed that the opportunistic pathogen Staphylococcus aureus evolves resistance to the dual-targeting fluoroquinolone delafloxacin (DLX) that inhibits both the DNA gyrase and DNA topoisomerase IV via amplification of an efflux pump encoding gene sdrM...Finally, loss of function mutants of the tyrosine recombinase XerC, that is known to play a role in chromosomal separation, were deficient for sdrM amplification, indicating that XerC is a novel modulator of gene amplification, or the maintenance or selection of amplified gene copies. Thus, our work sheds light on genetic factors that alter gene amplification-mediated evolutionary trajectories to antibiotic resistance in S. aureus and can potentially unlock mechanisms by which such evolution of resistance can be inhibited."

Journal • Infectious Disease

The UK Antimicrobial Registry (UKAR): an overview of the first 20 months of recruitment. (PubMed, JAC Antimicrob Resist) - "UKAR is an ongoing prospective registry of adult inpatients prescribed 11 eligible study drugs (cefiderocol, ceftaroline, ceftazidime/avibactam, ceftobiprole, ceftolozane/tazobactam, dalbavancin, delafloxacin, eravacycline, imipenem/cilastatin/relebactam, meropenem/vaborbactam and oritavancin). The UKAR provides real-world data on the use of novel antimicrobials confirming they are sometimes used empirically as well as for directed therapy to treat both complex and common infections, and often for multiresistant pathogens. The study is a novel and important resource to support the judicious use of these drugs."

Journal • Critical care • Infectious Disease • Nephrology • Respiratory Diseases • Septic Shock

Sodium load of novel antibiotics: considerations for nephrologists and clinicians. (PubMed, Int Urol Nephrol) - "Parenteral antibiotics are an often-overlooked contributor to sodium intake. Clinicians should be aware of this hidden source in sodium-sensitive patients such as kidney disease patients. We propose a visual chart to support sodium-conscious antimicrobial selection as part of broader stewardship strategies."

Journal • Review • Chronic Kidney Disease • Nephrology • Renal Disease

Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus Causing Healthcare-Associated Bloodstream Infections in Brazil: Results from A Prospective Countrywide Multicenter Study. (PubMed, Infect Dis Ther) - "The recently reported ST105(CC5)-SCCmecII-t002 clone has disseminated in hospitals from different Brazilian regions, together with other lineages that have been previously associated with community-associated infections, composed a new molecular landscape of MRSA causing HA BSIs in Brazil."

Clinical • Journal • Infectious Disease

In vitro characterization of Delafloxacin activity against intracellular Legionella: exploring new treatment options for Legionnaires' disease. (PubMed, Int J Infect Dis) - "Based on the results obtained, the higher intracellular activity of delafloxacin compared to levofloxacin and its better safety profile should be confirmed in phase IV clinical real-life cases of Legionnaires' disease."

Journal • Preclinical • Infectious Disease • Pneumonia • Respiratory Diseases

Effect of pH on antimicrobial activity of delafloxacin against Escherichia coli isogenic strains carrying diverse chromosomal and plasmid-mediated fluoroquinolone resistance mechanisms. (PubMed, Microbiol Spectr) - "Ciprofloxacin MIC90 increased from 8 mg/L at pH 7.3 to 128 mg/L at pH 5.0, while delafloxacin MIC90 decreased from 64 mg/L to 16 mg/L. Using comprehensive resistance profiling across 81 isogenic strains and pharmacokinetic modeling, we demonstrate that delafloxacin could overcome treatment failures in acidic infection sites where conventional fluoroquinolones fail. These findings could have immediate clinical implications for treating urinary tract infections, abscesses, and biofilm-associated infections, potentially expanding therapeutic options against multidrug-resistant bacteria in previously challenging anatomical sites."

Journal • Infectious Disease • Nephrology

β-Lactamase inhibitors, cefiderocol and delafloxacin: evaluating promising antibiotics options for Pseudomonas aeruginosa in adults with cystic fibrosis. (PubMed, New Microbiol) - "High in vitro activity was observed for newer antibiotics such as ceftolozane-tazobactam (83% susceptibility), ceftazidime-avibactam (85% susceptibility), and cefiderocol (89% susceptibility). Delafloxacin also showed promising activity, with 93% of the isolates exhibiting MICs below the EUCAST epidemiological cut-off value. Results emphasize the potential utility of these agents."

Journal • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases

In Vitro Activity of Delafloxacin Against Corynebacterium spp. (PubMed, Antibiotics (Basel)) - " Fifty-three clinical isolates, assigned to five species of Corynebacterium spp., were evaluated using reference microdilution for delafloxacin, ciprofloxacin, levofloxacin, and moxifloxacin (with and without reserpine or phenylalanine-arginine β-naphthylamide), and gradient strips for delafloxacin. Delafloxacin gradient strips could be a reasonable alternative for use in the clinical routine of the microbiology laboratory. Delafloxacin could represent an alternative for treating infections due to some species of Corynebacterium."

Journal • Preclinical • Infectious Disease

A Randomized, Observer-Blinded, Active-Controlled, Phase IIIb Study to Compare IV/Oral Delafloxacin Fixed-Dose Monotherapy With Best Available Treatments in a Microbiologically Enriched Population With Surgical Site Infections: The DRESS Study. (PubMed, Open Forum Infect Dis) - P3 | "In this randomized, observer-blinded, active-controlled, parallel-group, multicenter, phase IIIb study, patients with SSI were randomized 1:1 to receive delafloxacin 300 mg intravenous (IV)/450 mg oral (OS) or BAT IV/OS (vancomycin or linezolid for cardiothoracic SSI, piperacillin/tazobactam or tigecycline for abdominal SSI)...This study provided new data on delafloxacin in SSIs, covering the need for effective empiric treatment against the wide spectrum of pathogens involved in these infections. NCT04042077; 2018-001082-17 (EudraCT)."

Clinical • Journal • Monotherapy • P3 data • Infectious Disease

An evaluation of antibiotic options for the treatment of biothreat pathogens. (PubMed, Front Antibiot) - "This review includes finafloxacin, levofloxacin, delafloxacin, omadacycline, gepotidacin, tebipenem and sulopenem. The selection criteria of these antibiotics were 1) the availability of an oral formulation, 2) the regulatory status (licensed by a regulatory authority or in an advanced stage of development) and 3) the availability of publicly available information on the biodefence pathogens of concern. We hope to highlight approved or advanced clinical candidates that have significant and unique potential in the biodefense space which may be deployed to protect both the public and warfighter against these bacterial infections."

Journal • Review • Infectious Disease

Activity of Delafloxacin and Comparator Agents Against Bacterial Isolates From Patients with Diabetic Foot Infection in the United States and Europe (2017–2023) (IDWeek 2025) - No abstract available

Clinical • Infectious Disease